988 related articles for article (PubMed ID: 25843270)
1. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
Greenberg DP; Robertson CA; Talbot HK; Decker MD
Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.
Chu K; Xu K; Tang R; Tian X; Hu J; Yang T; Li C; Hu Y; Zeng G
Vaccine; 2020 Aug; 38(37):5940-5946. PubMed ID: 32732142
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial.
Vesikari T; Virta M; Heinonen S; Eymin C; Lavis N; Chabanon AL; Gresset-Bourgeois V
Hum Vaccin Immunother; 2020 Mar; 16(3):623-629. PubMed ID: 31526225
[TBL] [Abstract][Full Text] [Related]
17. Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
Claeys C; Drame M; García-Sicilia J; Zaman K; Carmona A; Tran PM; Miranda M; Martinón-Torres F; Thollot F; Horn M; Schwarz TF; Behre U; Merino JM; Sadowska-Krawczenko I; Szymański H; Schu P; Neumeier E; Li P; Jain VK; Innis BL
BMC Infect Dis; 2018 Apr; 18(1):186. PubMed ID: 29669531
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
Ofori-Anyinam O; Leroux-Roels G; Drame M; Aerssens A; Maes C; Amanullah A; Schuind A; Li P; Jain VK; Innis BL
Vaccine; 2017 Nov; 35(46):6321-6328. PubMed ID: 28987445
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
